Q-omics provides the consensus-scored FOXI1 profile across patient tissues and cancer cell-line models. FOXI1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FOXI1 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, FOXI1 RNA expression shows 8,661 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KIRC, and THYM as cancer lineages where FOXI1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FOXI1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FOXI1 survival associations across molecular data types. FOXI1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FOXI1 RNA expression–survival associations across cancer types. High FOXI1 expression shows unfavorable associations in COAD, DLBC and UCEC, but favorable associations in ACC, STAD and READ. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .015). Together, the overview and detailed table identify ACC as the clearest survival context for FOXI1 RNA expression.
This table summarizes FOXI1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FOXI1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FOXI1 shows lower tumor expression in KIRC, KIRP, HNSC, THCA and BRCA and higher tumor expression in KICH. The KIRC box plot shows higher FOXI1 RNA expression in normal versus tumor tissue (log2 FC = −5.557, t-test p < 0.001).
This table shows molecular features associated with FOXI1 in patient tissues and cancer cell lines. In patient samples, FOXI1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FOXI1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LUNG_NSCLC_LUAD.
